Quantcast

Latest Lexicon Pharmaceuticals Inc. Stories

2014-07-09 08:27:32

Trial to Evaluate Efficacy and Safety of LX4211 in Younger Population THE WOODLANDS, Texas, July 9, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that JDRF, the world's largest non-profit supporter of type 1 diabetes (T1D) research, will provide funding to support a Phase 2, randomized, double-masked, placebo-controlled clinical trial to evaluate the efficacy and safety of LX4211 in a younger population with T1D. Up to 76 individuals with T1D,...

2014-07-07 16:24:29

THE WOODLANDS, Texas, July 7, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lonnel Coats has been appointed president and chief executive officer effective July 7, 2014. Mr. Coats most recently served as president and chief executive officer of Eisai Inc., the United States subsidiary of Eisai Co., Ltd. Mr. Coats joins Lexicon after 18 years of senior management experience with Eisai. As president and chief executive officer at Eisai, he...

2014-06-14 12:21:12

Results from Clinical Study in Type 2 Diabetes Patients with Renal Impairment and Preclinical Study in Type 1 Diabetes THE WOODLANDS, Texas, June 14, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), presented data at the 74(th) Scientific Sessions of the American Diabetes Association (ADA) in San Francisco on LX4211, an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) that is designed to lower blood glucose levels through...

2014-05-30 16:25:16

THE WOODLANDS, Texas, May 30, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3, 2014 at 9:00 AM EDT in New York City. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones. A webcast of the presentation will be available through Lexicon's website at www.lexpharma.com. An archived version of the...

2014-05-09 08:25:44

THE WOODLANDS, Texas, May 9, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the 2014 Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 13, 2014 at 1:00 PM PDT (4:00 PM EDT) in Las Vegas. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones. A webcast of the presentation will be available through Lexicon's website at www.lexpharma.com. An...

2014-05-08 08:31:12

Conference Call and Webcast at 11:00 a.m. Eastern Time THE WOODLANDS, Texas, May 8, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2014. "Consistent with our focus on late-stage drug development, we have made continued, excellent progress in the enrollment of patients in...

2014-05-05 08:27:39

Conference Call and Webcast to Follow THE WOODLANDS, Texas, May 5, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, will release its first quarter 2014 financial results on Thursday, May 8, 2014 before the financial markets open. Lexicon management will hold a conference call and webcast to discuss clinical development progress and financial results for the first quarter...

2014-04-14 12:32:44

Conference Call and Webcast at 8:30 a.m. Eastern Time THE WOODLANDS, Texas, April 14, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today positive, top-line results in a Phase 2 clinical trial of LX4211 in type 1 diabetes, which achieved the primary endpoint of reducing mealtime insulin use as well as several secondary endpoints, including improved glycemic control. LX4211 is an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2...

2014-04-03 08:28:59

THE WOODLANDS, Texas, April 3, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the Needham Healthcare Conference on Tuesday, April 8, 2014 at 9:20 AM EDT in New York City. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones. A webcast of the presentation will be available through Lexicon's website at www.lexpharma.com. An archived version of the presentation...

2014-02-28 08:24:53

Conference Call and Webcast at 11:00 a.m. Eastern Time THE WOODLANDS, Texas, Feb. 28, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2013. "We made important progress in our late-stage drug development programs in 2013, completing multiple studies of LX4211...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related